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Dr D. CraigMiller (Stanford, Calif). Thank you, Dr Bremner. I
would like all of you to keep your eyes on Eric Roselli, who is a
potential superstar in our field in the future. Not only is he trained
interventionally but he is also open-surgical trained. He can do a
transfemoral or transapical percutaneous aortic valve replacement
in the morning and then an open aortic valve replacement in the
afternoon. He can do a thoracic endovascular aortic repair (TE-
VAR) with the best of them, as well as open thoracoabdominal
or descending thoracic aortic aneurysm repairs. In my book, Eric
and others of his ilk represent the future for cardiovascular surgery.
I want to compliment him and the Cleveland aortic surgery group
for a clear analysis of a complicated group of patients. This work
was superbly presented.
Before we dig into the meat of this presentation, which actually
is pretty straightforward, there is an overarching general question
that I would like to ask. Of 353 patients who underwent a first-
stage arch replacement procedure with the elephant trunk, 156
were not accounted for in this analysis. They had died at the first
operation, they had died postoperatively, or they came back and
were either deemed not fit for a second-stage elephant trunk1416 The Journal of Thoracic and Cardiovascular Surcompletion procedure or declined it. Thus, you have this large
decrease in patient numbers from the initial arch operation to the
second-stage completion procedure. If you consider something
similar to a 5% to 10% operative risk for the initial arch replace-
ment, a 20% attrition rate in the interval between procedures,
and then another 5% to 10% or so death risk for the second-stage
elephant trunk completion procedure, that adds up to some serious
numbers. This excludes, of course, an unknown fraction in which
the descending aortic aneurysm or dissection does not enlarge.
Therefore, should we rethink this whole concept? Should we do
what Nick Kouchoukos has advocated for years: the arch-first
approach, in which one does the arch and descending thoracic or
thoracoabdominal aortic aneurysm aortic graft replacement simul-
taneously at 1 operation? In his most recent 2008 Annals of
Thoracic Surgery report of 51 patients with extensive chronic
aortic dissections, Dr Kouchoukos had a 4% operative mortality
rate, a 2% incidence of paraplegia, a 75% 5-year survival rate,
and a 90% estimate of freedom from reoperation at 7 years. We
all would agree that Dr Kouchoukos’ medium-term results are
truly excellent. About 56% of the patients in your series had a
chronic dissection and tended to be treated with an open surgical
second-stage procedure instead of endovascular completion. So,
would 1 large operation and, in Nick’s hands a safe one, be a better
alternative strategy to the 2-stage approach you reported today,
regardless of how the second stage is conducted? The downside
of Nick’s operation using a thoracosternotomy or bilateral sternot-
omy is major morbidity (eg, 18% required a tracheostomy), so
there certainly is a price to be paid. As with everything in life,
you either pay now or you pay later. What do you think, Eric, about
the larger overall picture? Should we give more thought to doing
these extensive thoracic aortic and thoracoabdominal procedures
in 1 stage?
Dr Roselli.Well, first of all, thanks for the kind comments. This
has been a really exciting experience treating these patients and us-
ing these new technologies.
What happens to these patients after the first-stage operation is a
question I cannot answer completely at this time. Right now, it
looks like we have done nearly 500 first-stage elephant trunk pro-
cedures at our institution, and we are in the process of collecting
the data because we do have a better practice of keeping track of
these folks. Many of these patients have undergone a first-stage
elephant trunk operation as a prophylactic measure. For example,
a patient with a 48-mm descending aorta is going to undergo an
elephant trunk when we have to replace the arch, but there
certainly are a certain percentage of patients who do die in the
interim or do not want to return for a second stage. I can tell you
from my own personal experience, whatever that is worth, that
when I do talk to the patients about having a stent graft up front
and the plan is to get the thing completed, they do come back. I
think that will make a big difference, but we are in the process
of combing through that data to have a better sense of it.
As far as the second comment about doing it all in 1 stage, I
think that also makes a lot of sense, and, you are right, it is still
a pretty morbid operation, even in Dr Kouchoukos’ excellent expe-
rience. Other options exist to do it in a first stage, and we do the
clamshell operation in Cleveland once in a while. My preference
if I have to perform an operation in 1 stage because the proximal
and distal aorta are both very large, however, is to use what Igery c December 2013
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Dterm a ‘‘frozen elephant trunk operation,’’ and I will put the stent
graft in through a sternotomy at the same time as the proximal
repair. We have had pretty good results in that group of patients
as well. We did not include any of those in this analysis, which
included only the 2-stage operations. However, I think as this tech-
nology improves and our understanding of how to treat these pa-
tients improves, we can tailor the approach. The clamshell
operation will still have a role, but I would not want to use it in
somebody with bad lungs. I would rather do a frozen elephant
trunk.
Dr Miller. Okay, good response. I would be interested in what
happened to those other patients. I am sure the patients are more
interested in returning if you promise them a stent graft rather
than a thoracotomy.
That gives rise to my second question. What is the big deal
about a second-stage completion procedure, no matter how you
do it? It is really not a high-risk procedure, as you have shown
today. The operative mortality and morbidity rates are low. In
fact, you were surprised that no difference was found in the early
results between the endovascular and open approaches, although
the TEVAR endovascular patients were older and sicker. In your
propensity score–adjusted matched cohorts, you could not show
that 1 approach was better than the other. Therefore, why would
you use a more palliative TEVAR procedure, instead of a much
more durable operation if no difference exists in the upfront risk?
Dr Roselli. It might be blasphemy for me to say so, but I do not
think the statistics can actually show us some of the finer details
and differences in these groups of patients, because the numbers
are just too small. There are clearly patients who have undergone
these operations as rescue attempts with these stent grafts for
whom we would never even think about doing an open operation.
This group of patients who we treated consists of patients who we
have considered with the broad eye of having all the treatment op-
tions in our armamentarium. The open operation is good, the stent
graft is good, and there are patients who we just probably should
not treat at all, and we are still trying to determine which patients
belong in that last group.
Dr Miller. Good for you; you smelled my next question com-
ing. You do have the opportunity, the expertise, and the results
to prove you can use whichever method is best for that patient,
and I commend you for that. Why does not the rest of the world
have that capability? Are we ‘‘dumbing down’’ the entire field of
thoracic aortic disease treatment because many, if not most, cen-
ters cannot perform open thoracic aortic surgical repairs with
acceptable results or will not refer the patients to high-volume
regional referral surgical centers that can produce good results?
Instead, they insist on doing a hybrid arch or hybrid thoracoabdo-
minal TEVAR compromise procedure, which has not been associ-
ated with any less early risk and has limited short-term durability.
Are we ‘‘dumbing down’’ the entire field today?
Dr Roselli. That is a tough question to answer. To this audience,
I would say that is not a problem. I think there are cardiac surgeons
who call us all the time to send us these patients, understanding
that they need to be evaluated at a tertiary center that does a large
number of these operations. However, there certainly are places
where surgeons do come up with these unproven methods of treat-
ing patients. I know, for example, that at some of the vascular sur-
gical meetings I have listened to discussions of performing archThe Journal of Thoracic and Caroperations with a femoral to subclavian to carotid to carotid bypass
before putting a stent graft in. That makes no sense to me, to use a
leg-to-brain bypass in somebody before fixing their aorta when we
have very good proven techniques, but it happens. I do not know
how to fix that.
DrMiller.Well, like it or not, it will probably be the payors who
eventually are going to address this dilemma for us, and it will not
just happen in the United Kingdom. I predict there will be a US
equivalent of the British ‘‘NICE’’ committee, which will measure
cost effectiveness by calculating the ‘‘qualy’s’’ (quality years of
survival gained) against the cumulative cost and will then deter-
mine whether hospitals and physicians will be paid for a proce-
dure. That is where we will be forced to spend our limited
resources. This delicate point relates to my final question: Philippe
Demers at this meeting in 2003 presented the mid-term outcomes
for our first 103 thoracic aortic stent graft TEVAR patients from
Stanford. Two thirds of the patients had been deemed inoperable
by Scott Mitchell or myself, and the 5-year survival rate after TE-
VAR was dismally low—31%  6%—for this cohort, because, as
one might have expected, they mostly died of complications from
their multiple medical comorbidities even if aneurysm rupture was
prevented. This led us to conclude on philosophical grounds that
TEVAR should not be performed in asymptomatic patients who
were judged by a cardiovascular surgeon not to be fit enough to un-
dergo open surgical graft replacement (J Thorac Cardiovasc Surg.
2004;127:664-73). No matter how one assesses the ‘‘qualy’s’’ for
these unfortunate patients, TEVAR just does not compute. Eric,
what are the sentiments of you and your colleagues concerning
how we address these issues about the allocation of fixed US
healthcare resources in the future?
Dr Roselli. Again, that is another difficult problem. We see it
not only with patients with thoracic aortic disease who have a
limited lifespan no matter what we do, but also we are seeing it
more and more in these groups of patients with severe aortic steno-
sis who are being evaluated for transcatheter valve replacement.
How do you define the highest risk group of patients? I think we
need to just ensure that we collect the data on all these patients
we treat and the ones we do not treat to have a better understanding
of what happens.
Dr Miller. Again, a great presentation and welcome to the
Western Thoracic.
Dr Roselli. Thank you.
Dr Richard Lee (Chicago, Ill). Eric, again congratulations on
this contribution. I think your data, regardless of the statistical
analysis, do suggest that for the early mortality or near early mor-
tality, the procedure itself caused a lot of mortality in the open
group. For the late mortality, it evens out. Any insight into the
cause of mortality in the late group and are there any mortalities
due to the endovascular repair in the late group?
Dr Roselli.Great question, Rick. Thanks. So far, the late deaths
that I have been able to determine the cause of have been because
of various etiologies. Several patients died of cancer. I have seen 1
patient die of aortic disease—a patient who would not return for
follow-up—who died of an abdominal aneurysm that was sched-
uled to be repaired but ruptured. Another patient died of rupture
of a chronic dissection. However, most of them have been age-
related illnesses, less so aortic-related deaths, from what we can
tell at this point.diovascular Surgery c Volume 146, Number 6 1417
